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1 |  INTRODUCTION
Medulloblastoma (MB), a heterogeneous solid tumor of 
the posterior fossa, is the second most common malignant 
pediatric brain tumor after high-grade gliomas (Millard & 
De Braganca, 2016; Ostrom et al., 2015). Typically, medul-
loblastomas (MBs) are aggressive and metastasize within 
the central nervous system and, less frequently, outside the 
neuraxis (Millard & De Braganca, 2016). The four consen-
sus subgroups, MBSHH, MBWNT, MBGroup3, and MBGroup 
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Abstract
Background: Medulloblastomas (MBs) are a heterogeneous group of childhood 
brain tumors with four consensus subgroups, namely MBSHH, MBWNT, MBGroup 3, 
and MBGroup 4, representing the second most common type of pediatric brain cancer 
after high-grade gliomas. They suffer from a high prevalence of genetic predispo-
sition with up to 20% of MBSHH caused by germline mutations in only six genes. 
However, the spectrum of germline mutations in MBSHH remains incomplete.
Methods: Comprehensive Next-Generation Sequencing panels of both tumor and 
patient blood samples were performed as molecular genetic characterization. The 
panels cover genes that are known to predispose to cancer.
Results: Here, we report on a patient with a pathogenic germline PTEN variant re-
sulting in an early stop codon p.(Glu7Argfs*4) (ClinVar ID: 480383). The patient 
developed macrocephaly and MBSHH, but reached remission with current treatment 
protocols.
Conclusions: We propose that pathogenic PTEN variants may predispose to medul-
loblastoma, and show that remission was reached with current treatment protocols. 
The PTEN gene should be included in the genetic testing provided to patients who 
develop medulloblastoma at an early age. We recommend brain magnetic resonance 
imaging upon an unexpected acceleration of growth of head circumference for pedi-
atric patients harboring pathogenic germline PTEN variants.
K E Y W O R D S
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4, exhibit distinctive transcriptional and epigenetic signa-
tures that define clinically relevant patient subsets (Vladiou 
et al., 2019). However, an incomplete understanding of the 
underlying molecular etiology in each subgroup has im-
peded the development of specific treatment modalities 
(Vladiou et al., 2019).
MBs account for roughly 10% of central nervous system 
malignancies in children between 0 and 14 years of age with 
a worldwide age-adjusted incidence of 2.0–5.8 cases per 
1,000,000 annually (Millard & De Braganca, 2016; Waszak 
et al., 2018). The incidence peaks in two age groups, namely in 
children between 3 to 4 years and 8 to 9 years of age (Millard & 
De Braganca, 2016; Ostrom et al., 2015). Extensive single-cell 
transcriptomics have revealed that MBs originate from irreg-
ularities in early brain development (Vladiou et  al.,  2019), 
which may explain why at least 70% of MBs occur in the pe-
diatric population (Millard & De Braganca, 2016).
A recent study demonstrated that the MBSHH subgroup 
suffers from the highest prevalence of genetic predisposi-
tion (approximately 20%) with recognized germline driver 
mutations in APC, BRCA2, PALB2, PTCH1, SUFU (OMIM 
*607035), and TP53 (Waszak et  al.,  2018). However, the 
spectrum of germline mutations in MB remains incomplete. 
Here, we present the first known case report of cerebellar 
medulloblastoma with an inactivating germline variant in the 
tumor suppressor PTEN (OMIM *601728). We suggest that 
pathogenic germline PTEN variants may predispose patients 
to the early development of medulloblastoma and show that 
current treatment protocols may prove effective despite the 
PTEN status. We recommend brain magnetic resonance im-
aging (MRI) upon an unexpected acceleration of growth of 
head circumference for pediatric patients known to harbor 
such variants of the PTEN gene.
2 |  RESULTS
2.1 | Ethics statement
The patient and her legal guardians conferred an informed 
consent for the study. The study complies with the Helsinki 
Declaration of 1975.
2.2 | Methods
Histological characterization of the tumor was performed at 
the Department of Pathology (Oulu University Hospital, Oulu, 
Finland). Molecular genetics studies were performed using a 
Next-Generation Sequencing (NGS) panel at the Laboratory of 
Genetics, HUSLAB (Helsinki University Hospital, Helsinki, 
Finland). A comprehensive hereditary cancer NGS panel of 
blood sample DNA was performed at the Blueprint Genetics 
laboratory (Helsinki, Finland). The panel includes 116 genes 
known to confer a hereditary predisposition to cancer.
2.3 | Case report
The index patient was referred to the Oulu University 
Hospital at 14 months of age due to a 2-week history of tor-
ticollis and temper tantrums. She is the first child of her par-
ents, and the pregnancy and delivery were uneventful. Her 
birth weight, height and head circumference (+1.7 SD) were 
normal at birth. However, at the age of 2.5 weeks she pre-
sented with macrocephaly (+4.0 SD). The subsequent brain 
ultrasound and MRI were normal. Since the age of 5 months, 
her head circumference continued to grow on a +5 to +5.2 
SD curve. Brain MRI was repeated at the age of 6 months and 
brain ultrasound at the age of 7 and 9 months. All the find-
ings were normal. Otherwise, she developed normally and 
achieved walking at 12 months of age.
By admission to the hospital, the child had regressed to 
cruising. Macrocephaly had progressed (+6.3 SD) and MRI 
using a 1.5 Tesla scanner revealed a large cerebellar tumor 
(4.0  ×  5.5  ×  6.5  cm in size) with obstructive hydrocepha-
lus (Figure 1). The tumor was suspected to represent desmo-
plastic-nodular medulloblastoma by nodular MRI features. 
Subsequently, the patient underwent immediate ventriculo-
stomy and resection of the tumor mass. Complete resection 
was confirmed macroscopically and by postoperative MRI, 
and the child recovered as expected.
Post-surgical chemotherapy was performed accord-
ing to the SKK protocol in the HIT-MED Guidance of the 
University of Hamburg-Eppendorf for M0 tumors (with 
no postoperative residual tumor or metastases), between 
September 2017 and August 2018. Chemotherapy included 
Cyclophosphamide (1,200  mg/m2), Vincristine (16.5  mg/
m2), Carboplatin (3,000 mg/m2), Etoposide (2,250 mg/m2), 
and Methotrexate (30,000 mg/m2). The child is currently in 
remission at 3.5 years of age.
By NGS analysis, the tumor was shown to be wildtype 
for the PTCH1, SMO and TP53 genes, and MYC and MYCN 
amplifications were excluded. However, a SUFU (c.(412de-
linsCC), p.(Ala138Profs*32), NM_016169.3) mutation 
was discovered in an extended NGS panel confirming the 
MBSHH subtype (i.e., medulloblastoma, SHH-activated 
and TP53 wildtype). Additional mutations were found in 
the KDR (OMIM *191306, c.(787C>A), p.(Pro263Thr), 
NM_002253.2) and PTEN (c.(18dup), p.(Glu7Argfs*4), 
NM_000314.4) genes. The KDR variant is classified as 
pathogenic (COSM353283) but is unlikely to be significant 
here, since the developing medulloblastoma benefits from a 
functioning KDR gene (Slongo et al., 2007).
Finally, genetic counselling was provided as per the HIT-
MED Guidance for MBSHH. A DNA sample extracted from 
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the patient's blood was sent for sequencing. No known dis-
ease-causing germline variants associated with medulloblas-
toma were identified, including the APC, BRCA2, PALB2, 
PTCH1, SUFU, and TP53 genes (Waszak et  al.,  2018). 
However, the panel revealed a de novo heterozygous PTEN 
frameshift variant (c.(18dup), p.(Glu7Argfs*4)) leading to 
a premature stop codon and representing the same mutation 
observed in the tumor tissue. The PTEN variant has been 
classified as pathogenic (ClinVar ID: 480383). Another pa-
tient with a germline PTEN variant and medulloblastoma at 
1.0  years of age has previously been identified by Waszak 
and colleagues (Table  1) (Waszak et  al.,  2018). Gröbner 
et al. have reported two patients with germline PTEN vari-
ants and medulloblastoma at 19 and 23 years of age (Gröbner 
et al., 2018).
3 |  DISCUSSION
We present the first known case report of a toddler carrying 
a pathogenic germline PTEN variant with macrocephaly and 
MBSHH. While macrocephaly (+3.3 to 5.5 SD in males and 
+2.9 to 4.1 SD in females) is a known diagnostic feature 
of germline PTEN variants (Plamper, Gohlke, Schreiner, 
F I G U R E  1  Brain MRI showing a tumor of the posterior fossa of a 14-month-old girl. T2-weighted axial image (a) demonstrates a 
large cerebellar intraparenchymal hemispheric tumor with T2-hyperintense cystic (arrowhead) and T2-hypointense nodular solid (long arrow) 
components causing compression of the 4th ventricle (short arrow) and surrounding edema of the cerebellum (asterisk). Restricted diffusion of the 
solid components (b and c, arrows) suggesting highly cellular tumor is demonstrated on diffusion-weighted imaging (b) with apparent diffusion 
coefficient (ADC) map (c). The solid component is slightly hypointense compared to cerebellum on native T1-weighted image (d, arrow) but it 
enhances intensely with gadolinium contrast media showing nodular arrangement on contrast-enhanced T1-weighted axial (e) and coronal (f) 
images (arrows), which is indicative of desmoplastic nodular medulloblastoma. Lateral ventricles are dilated due to the compression of the tumor 
on the 4th ventricle (f, arrowheads). MRI, magnetic resonance imaging
(a) (b) (c)
(d) (e) (f)
T A B L E  1  Known germline PTEN variants associated with MB at infancy
Age Sex
Medulloblastoma  
subtype
Variant  
(cDNA)
Variant  
(protein) Pathogenicity ClinVar
1.0a F SHH c.(856delA) p.(Thr286ProfsTer5) NA NA
1.2 F SHH c.(18dup) p.(Glu7Argfs*4) Pathogenic 480383
Abbreviations: NA, not available; SHH, MBSHH.
aWaszak et al. (2018). 
4 of 5 |   TOLONEN ET aL.
& Woelfe,  2019; Tan, Mankad, Goncalves, Talenti, & 
Alexia,  2018), no imaging recommendations exist for fol-
low-up in macrocephaly (i.e., head circumference higher 
than 2 SD above the mean), particularly for patients with 
a positive family history of macrocephaly and no risk fac-
tors or neurological symptoms (Sampson, Berg, Huber, & 
Olgun, 2019; Tan et  al.,  2018). However, we suggest that 
PTEN variants may cause a predisposition to early medullo-
blastoma with implications for the timing of imaging studies.
The PTEN gene encodes a tumor suppressor protein with 
lipid and tyrosine phosphatase activities, and other non-en-
zymatic roles (Lee, Chen, & Pandolfi pp.,  2018; Pilarski, 
2019). Its main mode of action is to oppose the PI3K-AKT-
mTOR pathway to regulate cell proliferation and metabo-
lism as a potent suppressor of tumorigenesis (Sampson 
et  al.,  2019). Interestingly, tumorigenesis is promoted in a 
continuum of loss in PTEN activity (i.e., from subtle changes 
in expression and interaction with other proteins, to inacti-
vating mutations), which cancer cells achieve through mul-
tiple mechanisms (Lee et al., 2018). Thus, a heterozygous 
inactivation of the PTEN gene is sufficient to predispose to 
cancer (Lee et al., 2018; Liu, Wang, Wang, & Chan, 2019).
Consequently, point mutations in PTEN are observed 
in up to 37% of malignant tumors (Liu et al., 2019). The 
PTEN gene is associated with the PTEN hamartoma tumor 
syndrome including the overlapping Cowden (CS) and 
Bannayan-Riley-Ruvalcaba syndromes, the adult-onset 
Lhermitte-Duclos disease, and autism spectrum disorders 
with macrocephaly (Pilarski, 2019; Tan et al., 2012). Tan 
et al. (2012) have shown that patients with CS have an in-
creased lifetime risk (6%–85.2%) for cancers of the breast, 
thyroid, endometrium, colorectum, and kidney, as well as 
melanoma, and a robust, evidence-based follow-up strategy 
of patients with germline PTEN mutations has been pro-
posed. The current follow-up protocols begin in adulthood 
or 5–10  years prior to the earliest incidence of a certain 
cancer type in the family (Eng, 2001). Notably, no cases of 
medulloblastoma were observed in the cohort of 368 pa-
tients harboring germline PTEN variants followed up by 
Tan and colleagues (Tan et al., 2012).
In contrast, recent studies implementing extensive NGS 
analyses have revealed that mutations in PTEN are also as-
sociated with adult and pediatric brain cancer (Gröbner 
et al., 2018; Robinson et al., 2012; Sturm et al., 2014; Waszak 
et al., 2018). A study by Gröbner et al. (2018) reported that 
5% of a total of 42 cases of MBSHH in their cohort were asso-
ciated with germline PTEN variants, suggesting, in addition, 
that pediatric tumors demonstrate a rate of new mutations that 
is 14 times lower than that observed in adult cancer, suffer-
ing, instead, from a higher incidence of germline mutations 
(7.6%). Furthermore, their data suggest that 57% of pediatric 
cancer harbor a single driver mutation and that 50% of these 
mutations are druggable. Similarly, Waszak and colleagues 
established that germline mutations explain 5%–6% of medul-
loblastoma, most significantly in the APC, BRCA2, PALB2, 
PTCH1, SUFU and TP53 genes, with SUFU and PTCH1 
mutations demonstrating a high prevalence in infant MBSHH 
(Waszak et al., 2018). Their data include one pathogenic ger-
mline PTEN variant associated with MBSHH (out of approx-
imately 41 cases of MBSHH with genetic predisposition) and 
show that familial history in MBSHH with a germline mutation 
is uncommon. These data suggest that damaging germline 
variants in PTEN, although rare, do occur in medulloblastoma.
Because the cases of medulloblastoma that are linked 
with germline PTEN variants are so rare—and may thus 
represent coincidental association—additional evidence is 
required to elucidate the role of PTEN in medulloblastoma 
predisposition. Mechanistically, PTEN regulates a perivas-
cular progenitor cell niche that may act as a platform for 
tumorigenesis (Zhu et al., 2016). The SHH and PI3K path-
ways converge to promote the proliferation of granule cell 
progenitors in the external granule layer of the cerebellum. 
The Pten−/− mouse model produced by Zhu and colleagues 
demonstrated irregular proliferation of the progenitors, 
which progressed to fully penetrant MBBSHH with a co-de-
letion of the Tp53 gene. It is possible that PTEN variants 
predispose to a rapidly developing medulloblastoma but re-
quire a mutation in one or several “second genes” for tumor-
igenesis (Gröbner et al., 2018; Zhu et al., 2016). This might 
explain the infrequency of medulloblastoma in patients with 
germline PTEN variants. Accordingly, the extended NGS 
panel of our patient's tumor DNA revealed a point mutation 
in SUFU which has been implicated in the development of 
MBSHH (Brugières et al., 2012; Waszak et al., 2018).
In conclusion, we report on a patient with macrocephaly 
and MBSHH that developed before the first typical peak in 
medulloblastoma incidence at 3 to 4 years of age. Extensive 
NGS analyses revealed a pathogenic germline variant in PTEN 
and a second variant of the SUFU gene in the tumor DNA. 
Notably, remission was reached with current medulloblas-
toma treatment protocols despite the PTEN status. As certain 
countries are beginning to provide whole-genome sequencing 
for all newly diagnosed pediatric cancer patients (Byrjalsen 
et  al.,  2018), coincidental germline variants may confound 
the search for true genetic predisposition in pediatric cancer. 
We therefore suggest that the genetic testing of young patients 
with medulloblastoma should include the PTEN gene in ad-
dition to the APC, BRCA2, PALB2, PTCH1, SUFU and TP53 
genes with well-defined associations to medulloblastoma to 
characterize the role of PTEN in the development of medul-
loblastoma. Genetic counseling should be provided to families 
where germline mutations have been revealed.
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